BioCentury
ARTICLE | Company News

J&J drops Achillion HCV deal

September 15, 2017 9:09 PM UTC

Johnson & Johnson (NYSE:JNJ) terminated a 2015 deal with Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) to develop and commercialize HCV therapies, including triplet therapy JNJ-4178. J&J said it decided to discontinue development of JNJ-4178 “in light of the increasing availability of a number of highly effective therapies addressing the medical need in hepatitis C.”

J&J says it will shift its hepatitis R&D efforts to discovering a functional cure for HBV (see BioCentury, Aug. 11)...